^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    huCD33-BsAb

    i
    Other names: huCD33-BsAb, CD33*CD3 BsAb
    Associations

    News

    Trials
    Company:
    Y-mAbs Therap
    Drug class:
    CD3 agonist, CD33 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=3, Terminated, Y-mAbs Therapeutics | N=36 --> 3 | Trial completion date: Sep 2024 --> Dec 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Dec 2022; Study terminated due to business priorities
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    huCD33-BsAb